

# A new world of NGS A new day for precision oncology

Oncomine Solutions: an end-to-end workflow for clinical oncology research



## Broad genomic profiling by NGS is the foundation for advancing precision oncology



## Educational website

## Learn more about precision oncology research, next-generation sequencing, and Oncomine<sup>™</sup> Solutions at oncomine.com

- Learn about our comprehensive portfolio of products
- Hear from our customers
- Access on-demand webinars, infographics, and articles

### Jose Luis Costa.

**Clinical Researcher at the Ipatimup Center and** Head of Molecular Assay Development Unit of Affiliated Professor at the Department of Pathology, the Institute of Medical Genetics and Pathology, University of Porto Faculty of Medicine, Portugal, University Hospital Basel, was an early tester of the was an early tester of the Genexus System. He says: Genexus System. He says:

"The instrument is extremely intuitive. I would "The Ion Torrent Genexus System is based on technology that has evolved over the last 10 say that it is simple enough for a child to use. Anyone–even without any expertise–can just plug years. I was an early adopter, so I have followed in the instrument and start working with it. It tells its entire development. The method, to the best of you exactly what to do, step by step. You don't my knowledge, has been cited in more than 6,000 really need to prepare in advance to work with it. scientific papers. Recently, a seminal retrospective In fact, the only thing you need is one pipette." study from the University of Heidelberg in Germany that used the Ion Torrent technology demonstrated a nearly 97 percent sequencing success rate across more than 3,000 non-small cell lung cancer samples, and a rejection rate, mostly due to quantity-not-sufficient errors, of only around 3 percent."

- Two user touchpoints
- 10 minutes of hands-on time



- Subscribe to get the news first
- Follow our blog to read what we and our customers think about hot topics

#### Philip Jermann,

Retrieved from "What is the real impact" in The Pathologist, December 2019

## **Oncomine Solutions**

Oncomine<sup>™</sup> Solutions offer end-to-end workflows that address specific challenges when implementing nextgeneration sequencing (NGS) for clinical oncology research. We understand that NGS applications and content need to be tailored for your lab's needs. That's why we offer two types of workflows, a broad assay portfolio, complete bioinformatics, and technical support, to suit the way you work.

Generus System Wor

Specimen to rep

Nucleic acid to rep

910

lon Genega

•

S5 Syst







Broad assay menu across key applications

## One size does not fit all

Oncomine Solutions give you options, because each individual, sample, and lab is unique



- New: Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> BCR IGH-LR Assay and Oncomine<sup>™</sup> BCR IGH-SR Assay
- New: Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Lymphoma Assay
- Coming soon: Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Myeloid MRD Assay
- Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Childhood Cancer Research Assay
- Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Myeloid Research Assay





- Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> TCR Beta-LR Assay
- Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> TCR Beta-SR Assay
- Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Tumor Mutation Load Assay





#### Liquid biopsy research solutions

- Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> cfDNA Assays for Lung, Breast, Colon
- Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Breast cfDNA Assay v2
- Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Lung Cell-Free Total Nucleic Acid Research Assay
- Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Pan-Cancer Cell-Free Assay

#### **FFPE** tissue testing solutions

- New: Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Precision Assay
- New: Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Comprehensive Assay Plus
- New: Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> tumor-specific panels
- Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Comprehensive Assay v3
- Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Focus Assay
- Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> BRCA Research Assay

## The importance of choosing the best technology for the purpose

### Low FFPE tissue sample input requirement is crucial



Formalin-fixed, paraffin-embedded (FFPE) tissue samples are often small, and the tumor content is limited in guantity and/ or quality. Oncomine assays require the least input of any commercially available assay and they have a proven record of high sequencing success. This enables labs to get results for maximum possible samples and save tissue sample for possible future further analysis.

1 out of every 8 samples. All samples

were able to be tested by method O.

### Not all NGS is the same: sample requirements can differ greatly from one test to the next

NGS-based testing input requirements are typically expressed in nanograms of nucleic acid, and can differ significantly between different NGS-based tests. The figures below explain the practical implications of these different requirements in terms of tissue, tumor area, and content. Even if similar numbers of slides are required for both tests, the tumor area and percentage of tumor content required are significantly higher for method F, in order for testing to be successful.



>25 mm<sup>2</sup>

### Translocation/fusion detection: two sides of the story

The lon Torrent<sup>™</sup> Oncomine<sup>™</sup> assays include a multifunctional approach to detect gene fusions in order to achieve a proper balance of strong performance on FFPE tissue with limited RNA input and comprehensive fusion detection.



### FusionSync<sup>™</sup> detection technology

Now you can detect novel and rare fusions without missing the known and common. This new technology for routine fusion detection in clinical research samples is designed to improve novel fusion detection. The targeted approach employs hundreds of fusion isoforms across varying partners and breakpoints to help ensure sensitive and specific detection of known fusions. In addition, exon tiling imbalance is available for ALK, FGFR1, FGFR2, FGFR3, NTRK1, NTRK2, NTRK3, and RET fusion drivers, which indicates not only the presence of an unknown fusion but also whether it will be a functional or nonfunctional fusion based on its impact on kinase domains.



Source: NGS to take top spot as cancer biomarker testing broadens. CAP TODAY, June 2018

>1 mm<sup>2</sup> and ≤5 mm<sup>2</sup>

31%

- 1. Targeted and therefore sensitive detection of **known** and recurrent fusion isoforms that constitute most of the fusions detected. Having specific designs for these isoforms is important to maximize their detection even in challenging situations when sample input or transcript levels are low.
- 2. Detection of novel fusions, which are rare events, is achieved by non targeted isoform detection and imbalance technology.



**NEW** 

# Oncomine Precision Assay on the Genexus System

**One-day turnaround time** 

successfully tested

### NGS with the speed and simplicity of IHC

The Oncomine Precision Assay on the new Genexus System is our next-generation solution for genomic profiling that empowers labs with an automated, hands-off workflow that takes you from FFPE tissue or plasma to report in one day.\*

It can be easily implemented in every lab, even without previous NGS experience, and will enable you to combine your lab's immunohistochemistry (IHC) results with an NGS profile of 50 key genes for a fast, comprehensive report.



### **Curated pan-cancer research content**

### **Molecular tagging**

- can be profiled

Less sample required, many more samples

samples tested 10 ng input

2 touchpoints and 10 min of hands-on time

\* Specimen-to-report workflow will be available after the Genexus Purification System and integrated reporting capabilities are added in 2020.



• Mutation, CNV, and fusion variant types across 50 key genes • Tumor suppressors, drivers, and resistance variants

### **Tissue and plasma samples**

• One test, one workflow, multiple sample types

• Maximizes samples that can be tested

• Accurate low-level variant detection

• Maximizes the number of tumors that

## Oncomine tumor-specific panels

## Because in precision oncology research, one size does not fit all

## Choose Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> tumor-specific panels for focused cancer research

The greater our knowledge about the genomic aberrations that may potentially cause cancer, the more we understand how heterogeneous it can be. While some aberrations can be found across many tumors, some are very specific to particular tumor types. An array of tools is required to provide relevant information for every cancer research sample while managing costs and available tissue material.

When available, Oncomine tumor-specific research panels will complement Oncomine assays, providing end-to-end solutions for researching the molecular profile of specific tumors from FFPE tissue samples.

- Small tumor-specific panels with relevant content for clinical research (15–30 genes)
- Available via **ampliseq.com** and manufactured on demand
- Low sample input requirement and robust performance on FFPE tissue
- End-to-end workflow, including bioinformatics and a reporting solution
- Specialized support for implementation





#### Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Bladder Panel

25-gene panel applicable to urothelial carcinoma, which represents ~90% of bladder cancers. Contains genes such as *PIK3CA*, *FGFR3*, and *ERBB2*.



#### Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> BRCA Expanded Panel

15-gene panel containing *BRCA1* and *BRCA2* as well as HR pathway genes important for ovarian, breast, and prostate cancer research. Contains genes such as *ATM*, *PALB2*, and *BRIP1*.



#### Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Colorectal and Pancreatic Panel

24-gene panel applicable to colorectal and pancreatic adenocarcinoma, including DNA mismatch repair pathway genes. Contains genes such as *APC*, *KRAS*, and *NRAS*.



#### Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Gastric and Esophageal Panel

17-gene panel applicable to gastric, esophageal, and gastroesophageal adenocarcinoma. Contains genes such as *TP53, ERBB2,* and *CDKN2A.* 



#### Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Gynecological Panel

19-gene panel applicable to endometrial cervical, and ovarian carcinomas. Contains genes such as *PTEN*, *BRCA2*, and *CTNNB1*.



#### Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Kidney Panel

15-gene panel applicable to renal cell carcinomas, the majority of kidney cancer. Contains genes such as *VHL*, *MTOR*, and *PBRM1*.



#### Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Liver Panel

22-gene panel applicable to hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Contains genes such as *TP53, MYC, TERT,* and *CTNNB1*.



#### lon Torrent<sup>™</sup> Oncomine<sup>™</sup> Lymphoma Panel

25-gene panel applicable to non-Hodgkin's lymphomas (primarily diffuse large B cell (DLBCL)) as well as to Hodgkin's lymphoma. Contains genes such as *BCL2, MYD*88, and *CARD11*.



#### Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Melanoma Panel

30-gene panel applicable to cutaneous and uveal melanoma. Contains genes such as *BRAF, NRAS,* and *CDKN2A*.





### Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Prostate Panel

21-gene panel applicable to prostate adenocarcinoma. Contains genes such as *AR*, *PTEN*, and *MYC*.

# **Oncomine Comprehensive Assay Plus**

## Comprehensive genomic profiling without compromises

Precision oncology research is quickly developing beyond single-biomarker profiling towards also assessing complex biomarkers. While this approach is still more prevalent in clinical research and not justified for every sample, it is important to be able to gain all of these genomic insights at once, when relevant.

The Oncomine Comprehensive Assay Plus is a broad, >500-gene assay that enables comprehensive genomic profiling by combining tumor mutational burden (TMB) and microsatellite instability (MSI) in a single assay.

This multibiomarker assay includes driver genes across all solid tumors, interrogates all classes of genomic alteration, and is enriched with gene variants to give you relevant insights.

- Minimum sample input
- Maximum results



## Simplify your journey to answers in hemato-oncology research

## The tools you need to expedite your path to hemato-oncology research insights in one place

Hemato-oncological disorders are complex and heterogenous diseases with many oncogenic drivers and subtypes.

Traditionally, the molecular research of myeloid and lymphoid malignancies have involved numerous single-Simplify and accelerate your research with our growing gene tests, multiple technologies, and laborious workflows. portfolio of hemato-oncology research assays. We make it easy for you to get everything you need in one place.

- 1 dedicated NGS partner
- 1 familiar workflow
- 1 comprehensive hemato-oncology research solution



\* The content provided herein may relate to products that have not been officially released and is subject to change without notice. For Research Use Only. Not for use in diagnostic procedures

In-house NGS testing enables you to consolidate and streamline your workflows, providing faster turnaround time (TAT), higher sensitivity, and potentially higher detection vield.



Oncomine Childhood Cancer Research Assay



Oncomine Myeloid Research Assay New: Oncomine Myeloid MRD Assay\*



New: Oncomine BCR IGH-LR Assay\* New: Oncomine BCR IGH-SR Assay\* New: Oncomine Lymphoma Assay\* Oncomine TCR Beta-SR

## End-to-end bioinformatics solution

The Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> informatics workflow presents a sample-to-report solution for data analysis, from initial sequence analysis of many variants to annotation of relevant cancer drivers, and a final report by Oncomine Reporter. This creates a simple, streamlined solution that doesn't require any specialized bioinformatics expertise.

Relevant cancer type findings				
Gene	Finding			
BRAF	BRAF V600E			
KIT	Not detected			
NTRK1	Not detected			
NTRK2	Not detected			
NTRK3	Not detected			

### Oncomine informatics workflow



Relevant biomarkers					
Genomic alteration	Relevant therapies (In this cancer type)	Clinical trials			
BRAF V600E B-Rail proto-oncogene, serine/threonine kinase Tiar: IA Allele Prequency: 20.00%	dabrafenib + trametinib <sup>1,2</sup> dabrafenib <sup>1,2</sup> trametinib <sup>1,2</sup> binimetinib <sup>1,2</sup> cetuxima, + vemurafenib <sup>1,2</sup> vemurafenib <sup>1,2</sup> BRAF inhibitor + MEK inhibitor	55			
NF1 R2450* neurofibromin 1 Tier: IIC Allele Frequency: 28.54%	None	6			
PIK3CA R88Q phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha Tier: IIC Allele Frequency: 27.15%	None	10			

### Oncomine Reporter software

- Oncomine Reporter software produces clear and concise reports
- Includes relevant biomarker data and associated therapies, guidelines, and global clinical trials
- Optimized for Oncomine assays across applications including FFPE tissue testing, liquid biopsy, TMB, and hematology-oncology, and cytogenetics

Example Health System			Example Health Systen 123 Stree City, State USA 00000C Tel +1 000-000-0000 email@examplehealth.con www.examplehealth.con	
	Sam	ple information		
Year of Birth:	1968	Primary Tumor Site:	Skin	
Gender:	Female	Sample Type:	Fresh-frozen	
Smoking Status:	Never Smoker	Sample ID:	00-123456789	
Case Number:	00-123456789	Sample Collected:	02/01/2018	
	nep	ort nignights		
Relevant biomarkers Therapies available Clinical trials		3 9 55		
Relevant biomarkers Therapies available Clinical trials	Relevant o	3 9 55 cancer type findings		
Relevant biomarkers Therapies available Clinical trials Gene	Relevant o	3 9 55 cancer type findings Finding		
Relevant biomarkers Therapies available Clinical trials Gene BRAF	Relevant o	3 9 55 cancer type findings Finding BRAF V600E		
Relevant biomarkers Therapies available Clinical trials Gene BRAF KIT	Relevant o	3 9 55 cancer type findings Finding BRAF VEODE Not detected		
Relevant biomarkers Therapies available Clinical trials Gene BRAF KIT NTRK1	Relevant c	3 9 55 cancer type findings BRAF V600E Not detected Not detected		
Relevant biomarkers Therapies available Clinical trials BRAF KIT MTRK1 MTRK2	Relevant o	3 9 55 cancer type findings Finding BRAF V600E Not detected Not detected Not detected		

### Global content standardized

Ion Torrent<sup>™</sup> Oncomine<sup>™</sup> Knowledgebase data are meticulously curated and updated quarterly. After data are collected from various global data sources, a team of experienced curation scientists manually reviews all candidate evidence. Two independent reviewers examine each piece of candidate evidence for context and standardization. The process has QC steps built in at various stages.

### Make it your own

The first page of the report can be customized to show the relevant biomarkers and variant details sections.

Templates can be customized with your logo, with custom text, and in one of 11 languages.

The report builder allows sections to be included and excluded as needed, enabling easy customization.



### Get information about clinical trials

Oncomine Reporter combines the data of thousands of enrolling clinical trials from more than 50 trial registries. Information on these relevant, open clinical trials can be filtered by region, country, and state and included in your report.



# When it comes to the NGS workflow, one size does not fit all



### Genexus System

The new Genexus System is the first turnkey NGS solution that automates the specimen-to-report workflow and delivers results in a single day with just two user touchpoints.\* The simplicity and practicality of the Genexus System means every lab can bring NGS in-house, regardless of the level of NGS expertise.

Compatible with the Oncomine Precision Assay, Oncomine Comprehensive Assay v3, Oncomine TCR Beta-LR Assay, and the Oncomine Myeloid Research Assay (coming soon).

# Get results for your routine samples with one-day TAT\* and minimum operational resources with the Genexus System and the Oncomine Precision

### Ion GeneStudio S5 System

The GeneStudio S5 system combines with the Ion Chef<sup>™</sup> Instrument for library preparation and templating, providing a highly automated NGS workflow with scalability. A single Ion GeneStudio S5 instrument can process several different chip sizes, allowing the instrument to handle multiple levels of throughput.

Compatible with all assays from the Oncomine portfolio except the Oncomine Precision Assay.

# Utilize the capacity of the Ion GeneStudio S5 instrument for projects requiring the full breadth of the Oncomine portfolio

\* Specimen-to-report workflow will be available after the Genexus Purification System and integrated reporting capabilities are added in 2020.

## Enable your oncology research with trusted Oncomine Solutions

Explore Oncomine Solutions at **oncomine.com** 



For Research Use Only. Not for use in diagnostic procedures. © 2020 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. **COL011205 0220**